Business:
Cancer Barrier Penetrating Therapies
Drug notes:
PRTH-627 RD undisclosed; PRTH-319 RD undisclosed; PRTH-103 RD solid tumors
About:
Incendia Therapeutics is creating a novel class of anti-cancer therapies to reprogram the tumor microenvironment (TME). Cancer cells manipulate their microenvironment to enhance their own survival. Incendia’s approach is to attack the structural and biochemical underpinnings of the TME to facilitate host immune cells to reach their targets. Incendia’s lead program is a physical barrier disruptor, PRTH-101 in phase I clinical trials. PRTH-101 is a monoclonal antibody that binds to and blocks the collagen receptor DDR1, disrupting collagen fiber alignment in cancer TMEs creating gaps in the barrier.
Clinical Trial Manager / Clinical Project Manager Cambridge, MA|56 days ago
VICE PRESIDENT / SENIOR VICE PRESIDENT CLINICAL DE... Cambridge, MA|66 days ago
R&D PROJECT MANAGER Cambridge, MA|100+ days ago